Moustafa B., Hille K., Ruprecht K. W.
University Eye Hospital, Homburg/Saar
Purpose: Hypopyon-Uveitis has been identified as a side effect in Patients with acquired immunodeficiency syndrome who are treated for Mycobacterium avium complex (MAC) infection with systemic rifabutin. We report a AIDS Patient with unilateral uveitis under therapy with rifabutin and hoch active antiretroviral therapy (HAART).
Method: A 37-year-old, human immunodeficiency virus (HIV)-positive man was initially seen with pain and decreased visual acuity in the right eye. Visual acuity was 0,5p. The right eye showed advanced iridocyclitis with cells in the anterior chamber, keratic precipitates, posterior synechiae and hypopyon (2mm). The posterior segment was unremarkable. He had a medical history of two years of a advanced HIV-Infection in stadium CDC C3. The patient was started on HAART, consisting of Retrovirâ, combivirâ, viramuneâ and combined antimycobacterial therapie with Rifabutin, Klacidâ, Tavanicâ, Cotrim forteâ and Myambutolâ since 2000.
Results: In our case the patient developed an anterior form of uveitis attribute to the toxic effect of Rifabutin. We stopped Rifabutin and begun with a local steroid (prednisolonacetat) and cycloplegia eyedrops. The patient showed a rapid recovery.
Conclusions: Because of lifelong HIV therapy with highly active antiretroviral chemo
Zurück | Back